How modified-risk claims affect demand for Copenhagen and General Snus
Official title: Ifluence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effect
Run by Roswell Park Cancer Institute · NCT07102082 · Data updated 2026-11-12
This project will test whether new 'modified risk' claims for Copenhagen and General Snus change daily smokers' interest in trying them and how much they'd be willing to pay.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Roswell Park Cancer Institute Academic / other |
| Locations | 1 site (Buffalo, New York) |
| Status | Recruiting |
| Started | September 25, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | June 1, 2026 |
| Trial ID | NCT07102082 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult daily cigarette smokers (at least 5 cigarettes per day for at least one year) who live in one of the eight specified Western New York counties, are open to trying non-combusted oral tobacco, and can complete online surveys are ideal candidates.
✕Probably not a fit
People who currently use smokeless tobacco at least weekly, have ever used Copenhagen or General Snus, plan to quit smoking within 30 days, are pregnant, or live outside the listed counties would not be eligible and are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study presents daily cigarette smokers with either a modified-risk claim or no claim for two smokeless tobacco brands and measures effects on product demand using an experimental auction and on perceived disease risk with questionnaires. Participants are recruited from eight counties in Western New York and complete online survey procedures. Key eligibility limits include daily smoking (≥5 cigarettes/day for ≥1 year), openness to trying non-combusted oral tobacco, and no recent smokeless tobacco use or prior use of the branded products. The design compares responses between claim and no-claim conditions to estimate how modified-risk messaging shifts willingness to pay and risk perceptions.
Why it matters
Potential benefit: If successful, the results could help regulators, clinicians, and public health officials understand whether modified-risk claims make smokers more likely to switch to or try smokeless products and how those claims change perceived health risk.
How similar studies have gone: Prior research on modified-risk claims for tobacco products is limited and mixed—some work shows such claims can lower perceived harm and increase product interest, while other studies raise concerns about misperception and unintended uptake.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Residing in one of the 8 counties of Western New York (Erie, Niagara, Cattaraugus, Chautauqua, Allegheny, Livingston, Genesee, Orleans, Wyoming). * Smoke cigarettes every day, at least 5 cigarettes per day, for at least 1 year. * Open to trying a non-combusted oral tobacco product. * Have access to a device (ie: computer/tablet/smartphone) with internet capabilities to participate in an online survey study. * Have the ability to read, write, and communicate in English. * Participant must understand the investigational nature of this study and an Independent Ethics Committee/Institutional Review Board approved information sheet prior to receiving any study related procedure Exclusion Criteria: * Plan to quit smoking in the next 30 days. * Use of smokeless tobacco at least weekly in the last 6 months. * Lifetime use (that is, ever used at any time prior to the study) of Copenhagen or General Snus. * Unwilling or unable to follow protocol requirements. * Pregnant or planning to become pregnant (by self report)
Where it's running
-
Roswell Park
Buffalo, New York, United States Recruiting
Study contacts
- Principal investigator: Richard O'Connor — Roswell Park
- Study coordinator: Ask Rpci
- Email: askroswell@roswellpark.org
- Phone: 1-800-767-9355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Omega-3s and low-dose aspirin for smokers with stage III periodontitis
In adults who smoke and have stage III periodontitis, this study tests whether adding omega-3 fatty acids and a small amount of aspirin to standard cleaning helps improve gum health.
-
Tirzepatide for Smoking Cessation in people who smoke and are overweight or obese
This study tests whether tirzepatide can help adults who smoke quit and manage weight better than placebo when combined with usual smoking-cessation support.
-
mHealth program for smokers who are unsure about quitting
This study will test two smartphone stop-smoking apps—one standard version and one with extra content for people not ready to quit—to see which better helps adults who are ambivalent about quitting smoking.
-
Stopping smoking before bronchoscopy or CT‑guided lung biopsy
This project tests whether offering immediate quit-smoking support and measuring nicotine markers helps people who smoke and are having a bronchoscopy or CT‑guided lung biopsy stop smoking.
-
Abuse potential of five modern oral nicotine products
This will test how five modern oral nicotine products compare with cigarettes and nicotine gum in how satisfying they feel and how much nicotine adult smokers absorb.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.